Medical Oncologist
The "grade" of a breast cancer describes how abnormal the cancer cells look under the microscope and how fast they are dividing. It is scored from 1 (slow-growing, cells still look fairly normal) to 3 (fast-growing, cells look very abnormal). Grade is found on your biopsy report and is a key part of how your team plans treatment — but it is not the same as the stage. At CION, your grade is one of several factors a tumour board weighs together when building your plan, with your first consultation free.
When a pathologist looks at your breast cancer cells under the microscope, they describe how different those cells are from normal breast cells, and how quickly they are dividing. That description is the grade. A low grade means the cells still look fairly normal and grow slowly; a high grade means they look very abnormal and grow quickly. Grade is reported on the same biopsy as your cancer type and receptor status.
Grade matters because, broadly, lower-grade cancers tend to behave less aggressively and higher-grade cancers more so. But grade is only one piece of the picture: it is combined with the cancer's stage, its receptor status, and markers like Ki-67 to build a full understanding of how your cancer is likely to behave and which treatments will help.
Grade 1 is low (cells look near-normal, slow-growing), grade 2 is intermediate, and grade 3 is high (cells look very abnormal, fast-growing).
Grade describes the biology and behaviour of the cancer cells themselves — not the size of the tumour or whether it has spread.
Grade is determined by a pathologist on biopsy or surgical tissue, alongside the type, ER/PR/HER2 status and Ki-67.
Grade and stage are two different things and people often confuse them. Grade describes how abnormal and fast-growing the cancer cells look under the microscope (scored 1 to 3). Stage describes how big the cancer is and how far it has spread (0 to 4). A small tumour can be high-grade, and a larger tumour can be low-grade — which is exactly why your team looks at both, not just one. Source: NCCN Breast Cancer guidance; WHO classification of breast tumours.
Breast cancers are graded from 1 to 3. The grade reflects how closely the cancer cells resemble normal cells and how actively they are dividing. It is a useful guide to behaviour, but it is an average — your own outlook depends on grade together with stage, receptor status and how you respond to treatment.
The cancer cells look quite similar to normal breast cells and are dividing slowly. Grade 1 cancers tend to grow and spread more slowly than higher grades and often have a more favourable outlook.
The cells look moderately abnormal and divide at a moderate rate — between grade 1 and grade 3. This is the most common grade, and treatment decisions often lean on receptor status and Ki-67 to refine the picture.
The cells look very abnormal and are dividing quickly. Grade 3 cancers tend to be more aggressive — but they are also often more responsive to chemotherapy, which is an important counterpoint.
A high grade is not a verdict. Many high-grade cancers respond very well to treatment, and grade is always weighed alongside stage and biology — never read in isolation.
Breast cancer grade is calculated using the Nottingham grading system (a modern version of the older Bloom-Richardson method). The pathologist scores three features of the cancer cells from 1 to 3 each, and adds them up. The total — between 3 and 9 — is then converted into grade 1, 2 or 3. It is an objective, standardised method used worldwide.
How much the cancer cells still organise themselves into the normal tube-like structures of breast tissue. The more normal structures they form, the lower the score.
How abnormal the nuclei (the control centres) of the cells look — their size and variation. More abnormal, varied nuclei score higher.
How many cells are actively dividing (in mitosis) in a set area. More dividing cells means faster growth and a higher score.
The three scores total 3–9. A total of 3–5 is grade 1, 6–7 is grade 2, and 8–9 is grade 3. This is the number that appears on your biopsy report.
This is the most common source of confusion for patients. Grade and stage sound similar but answer completely different questions. Understanding the difference helps you read your reports correctly and avoid unnecessary worry — a "grade 3" cancer is not the same as a "stage 3" cancer.
Grade (1–3) is found by looking at the cancer cells under the microscope. It tells you how abnormal and fast-growing they are. It is about biology, not size or spread.
Stage (0–4) is based on the size of the tumour, whether the lymph nodes are involved, and whether it has spread to distant organs. See our stages page for the full picture.
A tiny tumour can be high-grade (grade 3) but very early-stage (stage 1), and a larger tumour can be low-grade. That is why both are reported — they describe different aspects of the same cancer.
Your treatment is built from grade, stage, receptor status and your overall health together. Modern staging actually folds grade and receptor status into the final stage group.
A grade on a report means little on its own — what matters is how it is read alongside everything else about your cancer. CION's tumour board interprets your grade in the full context of stage, receptor status and your overall health, so your treatment fits you and nothing is over- or under-treated.
Talk to our team
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Woman-led, tumour-board-reviewed breast cancer care across 35+ centres in Telangana & AP. Call 1800-202-8726.
Grade does not, by itself, decide your treatment — but it is one of the factors that helps your team judge how aggressive the cancer is and whether chemotherapy is likely to add benefit. A higher grade generally signals faster-growing disease, which can make chemotherapy more useful; a lower grade, especially in a hormone-positive cancer, may mean chemotherapy adds little.
At CION, grade is always weighed together with stage and receptor status — never alone — when the tumour board designs your treatment plan.
Grade is closely related to another number you may see on your report: Ki-67. Both describe how fast the cancer is growing, but they measure it in different ways and complement each other. Together with receptor status, they give your oncologist a much fuller picture than grade alone.
You can read more about receptor and proliferation testing on our IHC and tumour markers page.
It is natural to read "grade 3" and feel alarmed. On average, higher-grade cancers do tend to behave more aggressively than lower-grade ones. But grade is just one factor among several, and a high grade alone does not determine your outcome — many high-grade cancers respond extremely well to treatment, and stage usually matters more for prognosis.
We give patients an honest, balanced picture. The most important levers — finding it early and treating it well — are exactly the things a tumour board and modern therapy can address.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
When you receive your diagnosis and reports, knowing what to ask helps you understand your own care. Here are the questions that matter most around grade — bring them to your consultation.
Ask your doctor to translate the number into plain language — how fast-growing the cells are and how that fits with the rest of your report.
Ask whether the grade is pushing toward or away from chemotherapy, and how it interacts with your receptor status.
Make sure you understand both numbers and that they are different — see our stages page to prepare.
If anything is borderline, ask whether a second pathology review or extra test (such as Ki-67 or a gene test) would help — a tumour board can advise.
A grade is just a number until someone explains what it means for you. CION offers a clear, woman-led pathway that turns your pathology report into a plan you understand — with your first consultation free.
A specialist reviews your biopsy in full and explains your grade, Ki-67 and receptor status in plain language — no rushed decisions, no unnecessary tests.
Where needed, we re-check or complete the grading and receptor testing, with up to 50% discounts on diagnostics, so the foundation of your plan is solid.
3+ oncologists read your grade alongside stage and biology, deciding as a team whether chemotherapy and other treatments will add benefit.
You leave with a clear plan and a clear explanation of why — with whole-person support and transparent costs throughout your care.
Hear from patients treated at CION — diagnosis, treatment path, and where they are today.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Talk to our team
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
The grade describes how abnormal the cancer cells look under the microscope and how fast they are dividing. It is scored from 1 to 3. Grade 1 (low grade) means the cells still look fairly normal and grow slowly; grade 2 is intermediate; grade 3 (high grade) means the cells look very abnormal and grow quickly. Grade is reported on your biopsy alongside the cancer type and receptor status. It is a useful guide to how the cancer is likely to behave, but it is always read together with the stage, the ER/PR/HER2 status and your overall health — never on its own.
No — this is the most common confusion, and they are genuinely different. Grade describes how the cancer cells behave (how abnormal and fast-growing they are), scored 1 to 3 from looking at them under the microscope. Stage describes how big the cancer is and how far it has spread, scored 0 to 4, based on tumour size, lymph node involvement and any distant spread. A small tumour can be high-grade but early-stage, and a larger tumour can be low-grade. Both are reported because they describe different aspects of the same cancer, and your treatment plan uses both together.
Breast cancer grade is calculated using the Nottingham grading system, a refined version of the older Bloom-Richardson method. A pathologist scores three features of the cancer cells from 1 to 3 each: tubule formation (how well the cells still form normal tube-like structures), nuclear pleomorphism (how abnormal the cell nuclei look), and mitotic count (how many cells are actively dividing). The three scores are added together, giving a total of 3 to 9. A total of 3–5 is grade 1, 6–7 is grade 2, and 8–9 is grade 3. It is an objective, standardised method used worldwide.
A grade 3 cancer is fast-growing, and on average high-grade cancers behave more aggressively than low-grade ones. But "grade 3" is not a verdict, and it is not the same as "stage 3". Grade is only one factor, and stage usually matters more for outlook. Importantly, high-grade cancers are often more sensitive to chemotherapy, so they can respond very well to treatment — sometimes shrinking dramatically before surgery. A grade 3 cancer found early generally has a much better outlook than a lower-grade cancer found late. We give patients an honest, balanced picture rather than focusing on one number.
Grade helps your team judge how aggressive the cancer is and whether chemotherapy is likely to add benefit. A higher grade signals faster-growing disease, which can make chemotherapy more useful. A lower grade — especially in a hormone-positive cancer — may mean hormone therapy is enough and chemotherapy adds little, helping avoid over-treatment. Grade never decides treatment alone: it is read together with receptor status and stage. In some intermediate-grade, hormone-positive cancers, a gene-expression test gives a clearer answer on whether chemotherapy is worthwhile. At CION the decision is made by a tumour board considering all of these together.
Ki-67 is a marker measured by immunohistochemistry and reported as a percentage — the proportion of cancer cells that are actively dividing. Like grade, it describes how fast the cancer is growing, but it measures it differently, so the two complement each other. A higher Ki-67 usually goes with a higher grade, and a lower Ki-67 with a lower grade. When they agree, the picture is clear; when they differ, the team looks more carefully. In borderline cases — particularly intermediate-grade, hormone-positive cancers — Ki-67 can help decide whether chemotherapy is worthwhile, often alongside a gene-expression test.
Sometimes. The grade from a needle biopsy is based on a small sample, so the grade reported on the larger surgical specimen can occasionally differ slightly — usually only by one step. This is one reason the final pathology after surgery is so important and why your full report is reviewed carefully. If you have had chemotherapy before surgery, the appearance of any remaining cancer can also change. At CION, both the biopsy and final pathology are reviewed by the tumour board, and any change is explained to you and factored into your ongoing plan.
Yes. CION offers a free first consultation for all cancer patients, including women who already have a biopsy report and simply want to understand their grade, Ki-67, receptor status and stage. It is a full 45-minute consultation — a specialist reviews your pathology, explains every number in plain language, and tells you what it means for treatment, with up to 50% discounts on diagnostics if any test needs repeating or completing. Your case is reviewed by a tumour board, so the interpretation is a team decision, not one person’s. You can book on 1800-202-8726 or request a callback through the form on this page.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.